Clinical Trials Logo

Solid Tumor Malignancy clinical trials

View clinical trials related to Solid Tumor Malignancy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05768269 Recruiting - Clinical trials for Hematological Malignancy

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

Start date: April 29, 2024
Phase:
Study type: Observational

This study is designed to collect long-term safety and survival data from participants previously treated in an eligible Century-sponsored index trial. This is an observational study, and the elements of the study design allow for important follow-up for safety, survival, and the continued evaluation of any late adverse events (AEs) that may appear after treatment with such cellular products. Additionally, collection of persistence data from participants will support the identification of any long-term risks or late AEs that may be causally related to treatment with such cellular products.

NCT ID: NCT05164016 Recruiting - Cancer Clinical Trials

Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients

Start date: June 29, 2022
Phase:
Study type: Observational

This study is being done because the investigators would like to learn more about how well the COVID-19 vaccine works in participants with cancer or those who have received a transplant or cellular therapy. Primary Objective Assess the immunogenicity to COVID-19 vaccination in patients with cancer and/or transplant and cellular therapy (TCT) recipients. Secondary Objectives - Evaluate the antibodies response to COVID-19 vaccination in immunocompromised patients. - Evaluate the T cell response to COVID-19 vaccination in immunocompromised patients. Exploratory Objectives - Assess incidence and severity of COVID-19 infections by 6 months following immunization with a SARS CoV-2 vaccine. - Assess the durability immune response to COVID-19 vaccination. - Assess the immunogenicity of COVID-19 vaccination in immunocompetent children and adolescents without cancer and have not undergone transplant or received cellular therapy.